<DOC>
	<DOCNO>NCT01687920</DOCNO>
	<brief_summary>This study estimate dose proportionality BAY94-8862 IR tablet .</brief_summary>
	<brief_title>Dose Proportionality Study With BAY94-8862 IR ( Immediate Release ) Tablets</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Healthy male subject Age : 18 46 year ( inclusive ) first screen examination Ethnicity : White Body mass index ( BMI ) : &gt; = 18 &lt; = 29.9 kg / mÂ² Clinically relevant finding ECG ( electrocardiogram ) second thirddegree AV block , prolongation QRS complex 120 msec Systolic blood pressure 100 140 mmHg Diastolic blood pressure 50 90 mmHg Heart rate 50 95 beats/ min Positive result hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immune deficiency virus antibody ( antiHIV 1+2 ) Participation another clinical study precede 3 month ( Last Treatment previous study First Treatment new study )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cardiac disorder</keyword>
</DOC>